Immunology Investor Event

Amlitelimab - Accelerated development program following compelling Ph 2 datal Rapid Phase 2b start following positive Phase 2a in AD in 2021 Atopic Dermatitis Asthma Other indications 34 Immunology Investor Event 2022 Phase 2b 2023 Phase 3 Ambition 2024 (subject to regulatory discussions) Phase 2b 2025 sanofi Phase 3 Phase 3 Plan to run Phase 3 in Atopic Dermatitis concurrently to Phase 2 Asthma Phase 2b starting in second half of 2022 Planned development programs for other indications to start in 2023

View entire presentation